Document:

Second Amended and Restated Voting Agreement

 Exhibit 10.17 
 IMPERIUM RENEWABLES, INC. 
 SECOND AMENDED AND RESTATED VOTING AGREEMENT 
 This Second Amended and Restated Voting Agreement (this “Agreement”), made and entered into as of February 7, 2007, amends
and supersedes in its entirety that certain Amended and Restated Voting Agreement (the “Existing Agreement”) dated as of October 30, 2006 by and among Imperium Renewables, Inc. (formerly Seattle Biofuels, Inc.), a
Washington corporation (the “Company”), the investors listed on Exhibit A and certain Investors listed on Exhibit A-1, thereto and hereto (each, an “Investor” and, collectively, with
their permitted transferees, the “Investors”), and the holders of Common Stock listed on Exhibit B thereto and hereto (each, a “Common Holder” and, collectively, with their permitted
transferees, the “Common Holders”). The Company, the Common Holders, and the Investors are individually each referred to herein as a “Holder” and are collectively referred to herein as the
“Holders.” Each Additional Investor, as defined below, who executes a counterpart of this Agreement, will be and become an additional “Investor” pursuant to this Agreement. 
 RECITALS 
 A. The Company and
certain Investors listed on Exhibit A-1 hereof (as supplemented from time-to-time, the “Additional Investors”) have entered into a Stock Purchase Agreement (as amended from time to time, the “Purchase
Agreement”) dated October 30, 2006 pursuant to which the Company desires to sell to the Additional Investors and the Additional Investors desire to purchase from the Company shares of the Company’s Series B Preferred
Stock (“Series B Preferred”). The Company, the Investors and the Common Holders each desire to facilitate the voting arrangements set forth in this Agreement, and the sale and purchase of shares of Series B Preferred
pursuant to the Purchase Agreement, by agreeing to the terms and conditions set forth below. For the purposes hereof, “Series A Preferred” refers to shares of the Company’s Series A Preferred Stock. For the purposes
hereof, the “Board” refers to the Company’s Board of Directors. 
 B. In connection with the Purchase Agreement,
the Company filed Amended and Restated Articles of Incorporation (the “Restated Articles”) that provide that, so long at least 500,000 shares of Series A Preferred and/or Series B Preferred are outstanding, the holders of the
Series A Preferred and Series B Preferred, voting as a single class, shall be entitled to elect two (2) directors to the Board (the “Series A/B Directors”); the holders of the Company’s Common Stock (the
“Common Stock”) shall be entitled to elect two (2) directors to the Board (the “Common Directors”); and the holders of the Series A Preferred, Series B Preferred and Common Stock, voting together
as a single voting group on an as-converted basis, shall be entitled to elect any remaining directors (the “Independent Directors”). 

 AGREEMENT 
 The parties hereby agree as follows: 
 1. Agreement to Vote. The Holders each agree to hold
all shares of the capital stock of the Company now owned or hereinafter acquired by them (the “Shares”) subject to, and to vote the Shares in accordance with, the provisions of this Agreement. In the event that, subsequent to
the date of this Agreement, any shares or other securities are issued on, or in exchange for, any of the Shares by reason of any stock dividend, stock split, consolidation of shares, reclassification or consolidation involving the Company, such
shares or securities shall be deemed to be Shares for purposes of this Agreement. 
 2. Board Size. The Shares shall be voted
at any annual or special meeting of shareholders of the Company (or the Holders shall consent pursuant to an action by written consent of the Company’s shareholders in lieu thereof) in such manner as to elect up to five (5) directors to
the Board, and the Holders will not vote the Shares, whether at any meeting or by written consent, for any amendment or change to the Company’s Bylaws or Articles of Incorporation providing for the election of more or less than five
(5) directors, or any other amendment or change to the Articles of Incorporation or Bylaws inconsistent with the terms of this Agreement. 
 3. Election of Directors. At each annual meeting of the shareholders of the Company, or at any meeting of the shareholders of the Company at which members of the Board are to be elected, or whenever members of the Board are to
be elected by written consent, the Holders agree to vote or act with respect to their Shares (to the extent such Shares are eligible to vote for such members of the Board) so as to elect: 
 3.1 Series A/B Directors. For so long as at least 500,000 shares of Series A Preferred and/or Series B Preferred are
outstanding, (a) a designee of Nth Power LLC and its affiliates (“Nth Power”) to serve as a Series A/B Director, so long so long as Nth Power owns at least 250,000 shares of Series A Preferred and/or Series B Preferred,
initially Nancy Floyd; and (b) a designee of Technology Partners and its affiliates (“Technology Partners”) to serve as the other Series A/B Director, so long so long as Technology Partners owns at least 250,000 shares
of Series A Preferred and/or Series B Preferred, initially Ira Ehrenpreis. On all matters relating to the election of the Series A/B Directors, the Holders agree to vote all of their Shares in favor of the election of the Series A/B Directors.

 3.2 Election of Common Directors. Two (2) members of the Board shall be designated by the holders of a
majority of the Common Stock (excluding any shares of Common Stock issued upon conversion of the Series A Preferred or Series B Preferred) to serve as the Common Directors, (a) one of whom shall be the Company’s Chief Executive Officer or
then-most senior executive officer, as appointed by the Board (the “Officer Designee”), initially Martin Tobias; and (b) the other of whom (the “Other Common Designee”) shall initially be John
Plaza. On all matters relating to the election of the Common Directors, the Holders agree to vote all of their Shares in favor of the election of the Common Directors. 
  

 -2- 

 3.3 Election of Outside Director. One (1) member of the Board shall be
designated by the mutual agreement of the Series A/B Directors and Common Directors to serve as an Independent Director, initially left vacant. On all matters relating to the election of the Independent Director, the Holders agree to vote all of
their Shares in favor of the election of the Independent Director. The Independent Director shall be a person who does not receive a salary (or other compensation for services provided) from the Company, from any Common Holder, from any of the
Investors or from any entity directly or indirectly controlled by, or under common control with, the Company, any Investor or any Common Holder, except for compensation received by such person from the Company solely in connection with serving as a
member of the Board. 
 4. Removal of Directors and Vacancies. Directors may be removed at any time with or without cause in
the manner allowed by law and in the Restated Articles and the Company’s Bylaws, provided, that no party shall vote for the removal of a director elected, nominated or designated pursuant to this Agreement, and no such vote shall be
effective, unless (a) in the case of directors nominated or designated pursuant to Section 3.1 or Section 3.2, the party or parties who nominated or designated such director, voting among themselves in accordance with Section 3
above, or (b) in the case of the Independent Director, a majority of the Series A/B Directors and Common Directors, provided such majority includes the Other Common Designee if Martin Tobias or John Plaza is not then serving as the Officer
Designee, shall specify. All Holders will vote for the removal of the Officer Designee if such person is no longer serving as the Company’s Chief Executive Officer or then-most senior executive officer. If such party or parties specify the
removal of a director, the other parties agree to vote all of their Shares, or as to which they have voting power, for the removal of such director. If a vacancy occurs on the Board, the remaining directors shall immediately appoint the nominee of
the group that elected, nominated or designated the departing director to fill such vacancy (or, in the case of the resignation and removal of the Officer Designee, the remaining directors shall immediately appoint the Chief Executive Officer or
then-most senior executive officer). If the remaining directors fail for any reason to elect such nominee, the Company or the party or parties shall cause a shareholders’ meeting to be held at the earliest practicable date (or cause a written
consent in lieu thereof to be circulated), at which meeting (or pursuant to such written consent) the other parties shall vote, pursuant to this Agreement, all of their Shares, or as to which they have voting power, for such nominee. 
 5. Additional Representations and Covenants. 
 5.1 Legends. Each certificate representing Shares held by the Common Holders or the Investors or any assignee of the Common Holders or Investors shall bear the following legend: 
 “THE SHARES EVIDENCED HEREBY ARE SUBJECT TO A VOTING AGREEMENT BY AND AMONG THE COMPANY AND CERTAIN SHAREHOLDERS OF THE COMPANY (A
COPY OF WHICH MAY BE OBTAINED FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO 

  

 -3- 

 
AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID VOTING AGREEMENT.” 
 5.2 Covenants of the Company. The Company agrees to use commercially reasonable efforts: (a) to assist in the
enforcement of the terms of this Agreement, including, without limitation, to cause the nomination and election of the directors as provided in Section 3; (b) to inform the parties of this Agreement of any breach of this Agreement (to the
extent the Company has knowledge thereof); and (c) to assist the parties of this Agreement in the exercise of their rights and the performance of their obligations under this Agreement. 
 6. Termination. 
 6.1 Termination Events. This Agreement shall terminate upon the earlier of: 
 (a) The upon the
consummation of the corporation’s sale of its Common Stock in a bona fide, firm commitment underwriting pursuant to a registration statement on Form S-1 under the Securities Act of 1933, as amended, with aggregate proceeds to the Company
of not less than $30,000,000 (after deducting any commissions or other expenses allowed, paid or incurred by the corporation for any underwriting), in connection with which all outstanding shares of preferred stock of the Company are converted to
Common Stock pursuant to the Restated Articles, or 
 (b) The effective date of a Corporate Event (as defined in the Restated
Articles). 
 6.2 Removal of Legend. At any time after the termination of this Agreement in accordance with
Section 6.1, any holder of a stock certificate legended pursuant to Section 5.1 may surrender such certificate to the Company for removal of the legend, and the Company will duly reissue a new certificate without the legend. 
 7. Miscellaneous. 
 7.1 Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter
hereof existing between the parties hereto are expressly canceled. 
 7.2 Successors and Assigns. The terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or
their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 7.3 Amendments and Waivers. Any term of this Agreement may be amended or waived (either generally or in a particular
instance and either retroactively or prospectively) only with the written consent of (a) the Company, (b) the holders of a majority of 

  

 -4- 

 
the Shares held by the Common Holders, and (c) the holders of at least two-thirds of the Shares held by the Investors; provided, however,
that (x) the written consent of Nth Power shall also be required for any amendment to, or waiver of, Section 3.1 of this Agreement (so long as Nth Power owns at least 250,000 shares of Series A Preferred and/or Series B Preferred), only to
the extent that such amendment or waiver would affect Nth Power’s designation rights thereunder, and (y) the written consent of Technology Partners shall also be required for any amendment to, or waiver of, Section 3.1 of this
Agreement (so long as Technology Partners owns at least 250,000 shares of Series A Preferred and/or Series B Preferred), only to the extent that such amendment or waiver would affect Technology Partners’ designation rights thereunder. Any
amendment or waiver effected in accordance with this Section 7.3 shall be binding upon the Company, each of the Common Holders, each of the Investors and each permitted transferee of any of the Shares. Notwithstanding the foregoing, all parties
hereby consent and authorize the Company to, and the Company shall, amend this Agreement, Exhibit A or Exhibit B, as the case may be, to effect the addition of (x) any officer, employee or other person who becomes a holder of the Common Stock
(including shares of Common Stock issued upon the exercise or conversion of an option or warrant), and (y) any other party, including holders of the Common Stock, as required by the Investors that hold a majority of the then outstanding Series
A Preferred and Series B Preferred voting as a single class, in each case without any further action by any of the parties. 
 7.4 Notices. Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or sent by fax (upon customary confirmation of
receipt), or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, addressed to the party to be notified at such party’s address as set forth on the signature page or Exhibit A
hereto, or as subsequently modified by written notice, and (a) if to the Company, with a copy to DLA Piper US LLP, Attention: Steven R. Yentzer, 701 Fifth Avenue, Suite 7000, Seattle, WA 98104, or (b) if to the Investors, with a copy to
Ronald Star, Howard Rice Nemerovski Canady Falk & Rabkin, A Professional Corporation, 3 Embarcadero Center, Suite 700, San Francisco, CA 94111. 
 7.5 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the
parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this Agreement, (b) the balance of the Agreement shall be interpreted as if such provision were so
excluded and (c) the balance of the Agreement shall be enforceable in accordance with its terms. 
 7.6 Specific
Enforcement. It is agreed and understood (a) that monetary damages would not adequately compensate an injured party for the breach of this Agreement by any party, (b) that this Agreement shall be specifically enforceable, and
(c) that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order. Further, each party hereto waives any claim or defense that there is an adequate remedy at law
for such breach or threatened breach. 
  

 -5- 

 7.7 Manner of Voting. The voting of the Shares pursuant to this Agreement
may be effected in person, by proxy, by written consent, or in any other manner permitted by applicable law. 
 7.8
Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Washington applicable to contracts executed in and to be performed in that state. 
 7.9 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and
all of which together shall constitute one instrument. 
 7.10 Titles and Subtitles. The titles and subtitles
used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 7.11 No Liability for Election of Recommended Directors. Neither the Company, the Common Holders, the Investors, nor any officer, director, shareholder, partner, employee or agent of any such party, makes any representation or
warranty as to the fitness or competence of the nominee of any party hereunder to serve on the Board by virtue of such party’s execution of this Agreement or by the act of such party in voting for such nominee pursuant to this Agreement.

 7.12 Aggregation of Stock. All shares of Series A Preferred and Series B Preferred held or acquired by
affiliated persons and entities (including affiliated venture capital funds and their partners, retired partners, members, former members and shareholders, or the estates and family members of any such partners, retired partners, members, former
members, shareholders and any trusts for the benefit of any of the foregoing persons) shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 7.13 Binding Effect. In addition to any restriction on transfer that may be imposed by any other agreement by which any
party may be bound, this Agreement shall be binding upon the parties, their respective heirs, successors and assigns and to such additional individuals or entities that may become shareholders of the Company and that desire to become parties hereto;
provided, that for any transfer of the Shares to be deemed effective, the transferee shall have executed and delivered an Adoption Agreement substantially in the form of attached Exhibit C. Upon the execution and delivery of an
Adoption Agreement by any transferee reasonably acceptable to the Company, such transferee shall be deemed to be a party hereto and a Holder hereunder as if such transferee’s signature appeared on the signature pages hereto. 
 7.14 Stock Splits, Stock Dividends, etc. In the event of any issuance of shares of the Company’s voting securities
hereafter to any of the parties hereto (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization or similar transaction), such shares shall become subject to this Agreement and shall be
endorsed with the legend set forth above. Wherever in this Agreement there is a reference to a specific number of shares of Common Stock, Series A Preferred or Series B Preferred or any other class 

  

 -6- 

 
or series of the equity securities of the Company, then, upon the occurrence of any of foregoing events, the specific number of shares so referenced in this
Agreement shall automatically be proportionally adjusted to reflect the effect on the outstanding shares of such class or series of stock by such event. 
 7.15 Amendment and Restatement of Existing Agreement. Pursuant to the Company’s receipt of the approvals required under the Existing Agreement in accordance with Section 7.3, given pursuant to
that certain Consent of Shareholders in Lieu of Special Meeting dated February 7, 2007 (the “Consent of Shareholders”), the Existing Agreement is deemed to be amended and restated in its entirety, and by execution of the
Consent of Shareholders, each of the Investors and Common Holders who were parties to the Existing Agreement are deemed to have executed this Agreement. 
 [Signature pages follow.] 
  

 -7- 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Voting Agreement as of the
date first written above. 
  

			
	COMPANY:
	
	IMPERIUM RENEWABLES, INC.
		
	By:	 	/s/ Martin Tobias
		 	Martin Tobias
		 	Chief Executive Officer

			
		
	Address:	 	 1418 Third Avenue, Suite 300
 Seattle, WA
98101

		
	Facsimile:	 	(206) 254-0204

 [Signature pages follow.]Common Stock Purchase Agreement

 Exhibit 4.1 
 COMMON STOCK PURCHASE AGREEMENT 
 THIS COMMON STOCK
PURCHASE AGREEMENT (this “Agreement”), dated as of June 28, 2007, is entered into by and between CryoCor, Inc., a Delaware corporation (the
“Company”) and Boston Scientific Scimed, Inc., a Minnesota corporation (“Purchaser”). 
 WHEREAS, concurrently herewith, the parties and Boston Scientific Corporation (“BSC”) have entered into a Development and License Agreement (the “License Agreement”); and

 WHEREAS, in connection with, and as a condition of the Company, Purchaser and BSC entering into, the License
Agreement, the Company and Purchaser have agreed to enter into this Agreement pursuant to which the Company may issue and sell to Purchaser, and Purchaser shall be obligated to purchase, under the circumstances described herein, up to $5,000,000 of
shares of the Company’s Common Stock, subject to the terms and conditions set forth herein. 
 NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

  

	1.	DEFINITIONS 

 Capitalized terms used
but not otherwise defined herein shall have the meanings provided in the License Agreement. In addition, the following terms shall have the respective meanings set forth below: 
 1.1 “Closing” means the First Closing or the Second Closing, as applicable. 
 1.2 “Common Stock” shall mean the Company’s common stock, $0.001 par value per share. 
 1.3 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. 
 1.4 “Financial Statements” shall mean, with respect to the latest date on which the
representation set forth in Section 3.1(g) is deemed to be made, the (i) audited, consolidated, balance sheet, statement of income and statement of cash flows of the Company as of the end of the most recently completed fiscal year which is
included in the Annual Report on Form 10-K most recently filed by the Company with the SEC prior to such date, and for the twelve (12)-month period ended on the last day of such fiscal year, and (ii) unaudited, consolidated balance sheet (the
“Balance Sheet”), statement of income and statement of cash flows, as of the end of the most recently completed fiscal quarter (the “Balance Sheet Date”) which is included in the Quarterly Report on
Form 10-Q most recently filed by the Company with the SEC prior to such date, and for the portion of the current fiscal year ended on the last day of such fiscal quarter. 

 1.5 “Legal Requirement” shall mean any federal, state, local, municipal,
foreign or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the
authority of any governmental authority. 
 1.6 “Material Adverse Effect” shall mean, with respect to the
Company, any change or effect that, when taken individually or together with all other adverse changes or effects, is or is reasonably likely to be materially adverse to the assets, business, results of operations, prospects or financial condition
of the Company and its subsidiaries, taken as a whole. 
 1.7 “Registration Rights Agreement” shall mean the
Registration Rights Agreement dated as of the date hereof between the Company and the Purchaser. 
 1.8 “SEC”
shall mean the Securities and Exchange Commission. 
 1.9 “SEC Filings” shall mean all reports, schedules,
forms, statements and other documents required to be filed by the Company with the SEC pursuant to the requirements of the Exchange Act, including material filed pursuant to Section 13(a) or 15(c) of the Exchange Act, in each case, together
with all exhibits, supplements, amendments and schedules thereto, and all documents incorporated by reference therein. 
 1.10
“Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 
 1.11 “Shares” shall mean the shares of Common Stock of the Company being purchased under this Agreement. 
  

	2.	PURCHASE AND SALE OF COMMON STOCK 

 2.1 Purchase and Sale of Stock. In consideration of and in express reliance upon, and subject to, the representations, warranties, covenants, terms
and conditions of this Agreement, the Company agrees to issue and sell to Purchaser, and Purchaser agrees to purchase from the Company, (i) in the First Closing, a number of shares of Common Stock equal to the quotient of $2,500,000 divided by
the First Closing Purchase Price (as defined below) and (ii) in the Second Closing, a number of shares of Common Stock equal to the quotient of $2,500,000 divided by the Second Closing Purchase Price (as defined below). The purchase price for
each Share in the First Closing shall be $6.79 (the “First Closing Purchase Price”). The purchase price for each Share in the Second Closing shall be the greater of (a) $2.53 and (b) the product of (i) the
average closing sales price of the Common Stock on the Nasdaq Stock Market for the 60 consecutive trading days prior to the Second Closing and (ii) 1.25 (the “Second Closing Purchase Price”). 
 2.2 Payment. At the First Closing, Purchaser will pay the aggregate First Closing Purchase Price, and, at the Second Closing, Purchaser will pay
the aggregate Second Closing Purchase Price, in each case for the Shares being purchased in such Closing, by wire transfer of immediately available funds in accordance with the Company’s wire instructions set forth on 

 
Exhibit A hereto. The Company will deliver to Purchaser the stock certificates representing the Shares against delivery of the aggregate First Closing
Purchase Price or Second Closing Purchase Price, as applicable, within five business days of the applicable Closing. No fractional shares or scrip representing fractional shares shall be issued in connection with the issuance of Shares pursuant to
this Agreement. 
 2.3 Closing Dates. 
 (a) The closing of the purchase and sale of the First Closing Shares contemplated by this Agreement (the “First Closing”) will take place on the date of execution of this Agreement and
will be held at the offices of the Company or at such other place as the parties agree. 
 (b) The closing of the purchase and sale of
the Second Closing Shares contemplated by this Agreement (the “Second Closing”) will take place within ten business days after the date that Milestone Five is deemed achieved pursuant to the terms of the License Agreement,
and will be held at the offices of the Company or at such other place as the parties agree. 
 2.4 No Rights as Stockholders. This
Agreement does not entitle Purchaser to any voting rights or other rights as a stockholder of the Company with respect to any Shares prior to the time of the Closing at which such Shares are purchased by the Purchaser. 
 2.5 Conditions Precedent to Purchaser Obligations. The obligation of Purchaser to purchase Shares in any Closing shall be further subject to the
satisfaction of each of the following conditions precedent on or before the date of such Closing: 
 (a) The representations and
warranties made by the Company in Section 3.1 hereof shall be true and correct in all material respects on and as of the applicable Closing. 
 (b) The Company shall have performed and complied in all material respects with all agreements, obligations and conditions in this Agreement, if any, that are required to be performed or complied with by it on or before the date of
the applicable Closing, and no material default by the Company shall exist under the License Agreement as of the date of such Closing. 
 (c) No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the transactions contemplated by this Agreement or under the License Agreement shall have been issued by any court
of competent jurisdiction and remain in effect, and there shall not be any Legal Requirement enacted or deemed applicable to the transactions contemplated by this Agreement or under the License Agreement that makes consummation of the transactions
contemplated by this Agreement or under the License Agreement illegal. 
 (d) The Company shall not be required to obtain stockholder
approval of the issuance of the Shares applicable to the given Closing in order to comply with the Marketplace Rules of the Nasdaq Stock Market or similar stockholder voting requirements that may be imposed on the Company by any other established
stock exchange or national market system on which the Common Stock is traded or listed. 

 (e) The Shares shall be listed on the Nasdaq Stock Market (which, for purposes of this Agreement,
includes the Nasdaq Global Market and the Nasdaq Capital Market), subject only to notice of issuance. 
 (f) The Company shall have
executed and delivered the License Agreement and the Registration Rights Agreement, and each of such agreements shall be in full force and effect. 
 (g) Notwithstanding anything to the contrary herein, Purchaser shall not be required to acquire any shares of Common Stock hereunder if, as a result of such acquisition, Purchaser would beneficially own more than such number of
shares as would require approval of such acquisition, this Agreement or the License Agreement by the Company’s stockholders in order to comply with the Marketplace Rules of the Nasdaq Stock Market or similar stockholder voting requirements that
may be imposed on the Company by any other established stock exchange or national market system on which the Common Stock is traded or listed (it being understood that to the extent that, and for so long as, any such stockholder approval would be
required, the Company shall not be obligated to issue such Shares under this Agreement). In such case, Purchaser shall be required to acquire such number of Shares as could be acquired without exceeding the limitation set forth above. 
 2.6 Conditions Precedent to Company Obligations. The obligation of the Company to consummate the sale of Shares in any Closing shall be further
subject to the satisfaction of each of the following conditions precedent on or before the date of such Closing: 
 (a) The
representations and warranties made by Purchaser in Section 3.2 hereof shall be true and correct in all material respects on and as of the date of the applicable Closing. 
 (b) No material default by Purchaser shall exist under the License Agreement as of the date of such Closing. 
 (c) No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the transactions
contemplated by this Agreement or under the License Agreement shall have been issued by any court of competent jurisdiction and remain in effect, and there shall not be any Legal Requirement enacted or deemed applicable to the transactions
contemplated by this Agreement or under the License Agreement that makes consummation of the transactions contemplated by this Agreement or under the License Agreement illegal. 
 (d) The Company shall not be required to obtain stockholder approval of the issuance of the Shares applicable to the given Closing in order to
comply with the Marketplace Rules of the Nasdaq Stock Market or similar stockholder voting requirements that may be imposed on the Company by any other established stock exchange or national market system on which the Common Stock is traded or
listed. 

 (e) Notwithstanding anything to the contrary herein, the Company shall not be required to issue
any shares of Common Stock hereunder if, as a result of such issuance, Purchaser would beneficially own more than such number of shares as would require approval of such issuance, this Agreement or the License Agreement by the Company’s
stockholders in order to comply with the Marketplace Rules of the Nasdaq Stock Market or similar stockholder voting requirements that may be imposed on the Company by any other established stock exchange or national market system on which the Common
Stock is traded or listed. In such case, the Company shall be required to issue such number of Shares as could be issued to Purchaser without exceeding the limitation set forth above. 
  

	3.	REPRESENTATIONS AND WARRANTIES 

 3.1 Representation and Warranties of the Company. The Company hereby makes the following representations and warranties to Purchaser as of the date of this Agreement and as of the date of each Closing, in each
case except (a) as set forth in the SEC Filings or (b) as contemplated by this Agreement: 
 (a) Organization, Good Standing and
Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business. The Company is duly qualified
to transact business as a corporation and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect upon the Company’s ability to perform its obligations under this Agreement or the
validity or enforceability of, or Purchaser’s rights and remedies under, this Agreement. 
 (b) Authorization; Due Execution. The
Company has the requisite corporate power and authority to enter into this Agreement and to perform its obligations under the terms of this Agreement. All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization, execution and delivery of this Agreement has been taken. This Agreement has been duly authorized, executed and delivered by the Company and, upon due execution and delivery by Purchaser of this Agreement, this
Agreement will be a valid and binding agreement of the Company, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights
generally or by equitable principles. 
 (c) Valid Issuance of Stock. The Shares, when issued, sold and delivered in accordance with
the terms of Section 2 hereof for the consideration and on the terms and conditions set forth herein, will be duly and validly authorized and issued, fully paid and nonassessable and, based in part upon the representations of Purchaser in this
Agreement, will be issued in compliance with all applicable federal and state securities laws, and will not be subject to any preemptive rights or other similar rights of shareholders of the Company that are provided for in the Company’s
Certificate of Incorporation, its By laws or in any agreement to which the Company is a party. 

 (d) No Defaults. There exists no default under the provisions of any instrument or agreement
evidencing, governing or otherwise relating to any material indebtedness of the Company, or with respect to any other agreement, a default under which could reasonably be expected to have a Material Adverse Effect upon the Company’s ability to
perform its obligations under this Agreement or the validity or enforceability of, or Purchaser’s rights and remedies under, this Agreement. 
 (e) SEC Filings. The Company has timely filed with the SEC all SEC Filings. The SEC Filings were prepared in accordance with and, as of the date on which each such SEC Filing was filed with the SEC, complied in all material respects
with the applicable requirements of the Exchange Act. None of such SEC Filings, including, without limitation, any financial statements, exhibits and schedules included therein and documents incorporated therein by reference, at the time filed,
declared effective or mailed, as the case may be, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. Except to the extent information contained in any of the SEC Filings has been revised, corrected or superseded by a later SEC Filing, none of the SEC Filings currently contains an untrue statement of a
material fact or omits to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 (f) Governmental Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing
with, any federal, state, local or provincial governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement, except for such notices required or permitted to be
filed with certain state and federal securities commissions after the date of this Agreement, which notices will be filed on a timely basis. 
 (g) Financial Statements. The Financial Statements are true and correct in all material respects, are in accordance with the books and records of the Company in all material respects and have been prepared in accordance with
generally accepted accounting principles consistently applied with the past practices of the Company (except as may be indicated in the notes thereto), and fairly and accurately present in all material respects the financial position of the Company
and the results of its operations for the periods then ended. The Company has no material liabilities, debts or obligations, whether accrued, absolute or contingent that under generally accepted accounting principles would be required to be
reflected in a consolidated balance sheet of the Company prepared as of the date of this Agreement except for: (i) liabilities identified as such in the “liabilities” column of the Balance Sheet; (ii) accounts payable or accrued
salaries that have been incurred by the Company since the Balance Sheet Date in the ordinary course of business; (iii) liabilities which have arisen since the Balance Sheet Date and, individually or in the aggregate, are not material to the
Company and its subsidiaries taken as a whole and that were incurred in the ordinary course of business; and (iv) liabilities under the Loan and Security Agreement dated on or about June 21, 2007, among the Company, Silicon Valley Bank,
Oxford Finance Corporation and ATEL Ventures, Inc. 

 (h) No Conflict. The Company’s execution, delivery and performance of this Agreement does not
violate any provision of the Company’s Certificate of Incorporation or Bylaws, each as amended as of the date hereof (copies of which have been filed with the Company’s SEC Filings), any provision of any order, writ, judgment, injunction,
decree, determination or award to which the Company is a party or by which it is bound, or, to the Company’s knowledge, any law, rule or regulation currently in effect having applicability to the Company. 
 (i) No Default or Violation. The Company is not (i) in default under or in violation of any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or any of its properties is bound or (ii) in violation of any order of any court, arbitrator or governmental body, the default or violation of which, individually or in the aggregate
would reasonably be expected to have a Material Adverse Effect. 
 3.2 Representations and Warranties of Purchaser. Purchaser hereby
makes the following representations and warranties to the Company as of the date of this Agreement and as of the date of each Closing: 
 (a)
Authorization; Due Execution. Purchaser has the requisite corporate power and authority to enter into this Agreement and to perform its obligations under the terms of this Agreement. All corporate action on the part of Purchaser, its officers,
directors and stockholders necessary for the authorization, execution and delivery of this Agreement have been taken. This Agreement has been duly authorized, executed and delivered by Purchaser, and, upon due execution and delivery by the Company,
this Agreement will be a valid and binding agreement of Purchaser, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’
rights generally or by equitable principles. 
 (b) Purchase Entirely for Own Account. This Agreement is made with Purchaser in
reliance upon Purchaser’s representation to the Company, which by Purchaser’s execution of this Agreement it hereby confirms, that the Shares purchased by Purchaser will be acquired for investment for Purchaser’s own account, not as a
nominee or agent, and not with a view to the resale or distribution of any part thereof, and that Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement,
Purchaser further represents that it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to such person or to any third person, with respect to the Shares, if issued. 

(c) Disclosure of Information. Purchaser has received all the information that it has requested and that it considers necessary or appropriate
for deciding whether to enter into this Agreement and to acquire the Shares. Purchaser further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the
Shares. 

 (d) Investment Experience. Purchaser is an investor in securities of companies in the development
stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in
the Shares, if issued. Purchaser also represents it has not been organized solely for the purpose of acquiring the Shares. 
 (e)
Accredited Investor. Purchaser is an “accredited investor” as such term is defined in Rule 501 of the General Rules and Regulations prescribed by the SEC pursuant to the Securities Act. 
 (f) Restricted Securities. Purchaser understands that: (a) the Shares will not be registered under the Securities Act by reason of a specific
exemption therefrom, that such securities must be held by it indefinitely and that Purchaser must, therefore, bear the economic risk of such investment indefinitely, unless a subsequent disposition thereof is registered under the Securities Act or
is exempt from such registration; (b) each certificate representing the Shares, if issued, will be endorsed with the following legends: 
 (i) THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED,
PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED; 
 (ii) Any legend required to be placed thereon pursuant to the Registration Rights Agreement, dated as of even date herewith, by and
between the Company and Purchaser; 
 (iii) Any legend required to be placed thereon by the Company’s Bylaws or
under applicable state securities laws; and 
 (c) The Company will instruct any transfer agent not to register the transfer of the Shares (or any
portion thereof) unless the conditions specified in the foregoing legends are satisfied, until such time as a transfer is made, pursuant to the terms of this Agreement, and in compliance with Rule 144 or pursuant to a registration statement or,
if the opinion of counsel referred to above is to the further effect that such legend is not required in order to establish compliance with any provisions of the Securities Act or this Agreement. 
  

	4.	COVENANTS 

 The Company covenants and
agrees that, during the term of this Agreement, it will: 
 4.1 Maintenance of Existence and Rights. Maintain and preserve in full
force and effect its existence and all rights, contracts, licenses, leases, qualifications, privileges, franchises and other authority necessary for the conduct of its business, and qualify and remain qualified to 

 
do business in each jurisdiction in which such qualification is material to its business and operations or ownership of its properties, except where the
lapsing of any of the foregoing would not cause or result in a Material Adverse Effect upon its ability to perform its obligations under this Agreement or the validity or enforceability of, or the other party’s rights and remedies under, this
Agreement. 
 4.2 Governmental and Other Approvals. Apply for, obtain and maintain in effect, as applicable, all material
authorizations, consents, approvals, licenses, qualifications, exemptions, filings, declarations and registrations (whether with any court, governmental agency, regulatory authority, securities exchange or otherwise) which are necessary in
connection with the execution, delivery and performance by such party of this Agreement, or any other documents or instruments to be executed or delivered by such party in connection herewith and the transactions consummated or to be consummated
hereunder. 
 4.3 Compliance with Laws. Comply in all material respects with all laws, rules and regulations applicable to such party,
except where such party’s failure to comply with any of the foregoing would not cause or result in a Material Adverse Effect upon such party’s ability to perform its obligations under this Agreement or the validity or enforceability of, or
the other party’s rights and remedies under, this Agreement. 
  

	5.	MISCELLANEOUS 

 5.1 Governing
Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding its conflicts of laws principles. The parties hereby expressly consent to the exclusive personal jurisdiction
and venue of the state and federal courts located in San Diego, California for any lawsuit filed by either party against the other arising from or related to this Agreement. 
 5.2 Market Stand-Off; Agreement Not to Sell. Purchaser shall not sell, dispose of, transfer, make any short sale of, grant any option for the
purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of, any Shares or other securities of the Company held by Purchaser (the “Restricted Securities”), for a period of time
specified by the managing underwriter (not to exceed ninety (90) days (or such longer period, not to exceed 18 days after the expiration of such 90-day period, as the underwriters or the Company shall request in order to facilitate compliance
with National Association of Securities Dealers Rule 2711)) following the effective date of a registration statement of the Company filed under the Securities Act. Purchaser agrees to execute and deliver such other agreements as may be reasonably
requested by the Company and/or the managing underwriter which are consistent with the foregoing and which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to Purchaser’s Restricted Securities until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 5.3 and shall have the right, power and authority to
enforce the provisions hereof as though they were a party hereto. 
 5.3 Assignment. This Agreement will inure to the benefit and be
binding upon each party, its successors and assigns. This Agreement may not be assigned or otherwise transferred, 

 
nor, except as expressly provided hereunder, may any right or obligation hereunder be assigned or transferred by either party without the prior written
consent of the other party; provided, however, that the Purchaser (and, following the Second Closing, the Company) may, without such consent, assign this Agreement and its rights and obligations hereunder in conjunction with a permitted
assignment of the License Agreement made in accordance with the terms thereof. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties. Any
attempted assignment not in accordance with this Section will be void. 
 5.4 Entire Agreement. This Agreement and the License
Agreement and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any
representations, warranties, covenants and agreements except as specifically set forth herein and therein. 
 5.5 Severability. In
case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 5.6 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement. 
 5.7 Notices. Any notice to be given under this Agreement must be in writing and delivered
either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the party to be notified at its address(es) given below, or at any address such
party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a) the date of actual receipt; (b) if mailed, three days after the date of postmark;
(c) if delivered by overnight courier, the next business day the overnight courier regularly makes deliveries; or (d) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient and, if not, then on the
next business day. 
 If to Purchaser, notices must be addressed to: 
 Boston Scientific Scimed, Inc. 
 c/o Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Attention: Chief Financial Officer 
 Phone: 508.650.8000 
 Fax: 508.650.8956 

 and 
 c/o Boston Scientific Corporation 
 2710 Orchard Parkway 
 San Jose, CA 95134 
 Attention: President-Electrophysiology 
 Phone: 408.895.3500 
 With a required copy to: 
 Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Attention: General Counsel 
 Phone: 508.650.8000 
 Fax: 508.650.8960 
 If to the Company, notices must be addressed to: 
 CryoCor, Inc. 
 9717 Pacific Heights Blvd. 
 San Diego, CA 92121 
 Attention: Gregory J. Tibbitts 
 Telephone: (858) 909-2200 
 Facsimile: (858) 909-2300 
 With a required copy to: 
 Cooley Godward Kronish, llp 
 4401 Eastgate Mall 
 San Diego, CA 92121 
 Attention: Matthew T. Browne, Esq. 
 Telephone: (858) 550-6045 
 Facsimile: (858) 550-6420 
 5.8 Counterparts. This Agreement may be executed in two
counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 
 [REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the parties hereto have duly
executed this Agreement as of the date first written above 
  

							
	BOSTON SCIENTIFIC SCIMED, INC.	 	CRYOCOR, INC.
				
	By:	 	 /s/ Paul Laviolette
	 	By:	 	 /s/ Edward F. Brennan

	Name:	 	Paul Laviolette	 	Name:	 	Edward F. Brennan, Ph.D.
	Title:	 	COO	 	Title:	 	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]